Abivax to present phase 3 ulcerative colitis trial results at UEG meeting

PARIS - Abivax SA (Euronext Paris:FR0012333284 - ABVX / Nasdaq: ABVX), a $6.3 billion market cap biotechnology company whose stock has surged over 1,000% year-to-date, announced Monday that results from its ABTECT Phase 3 induction trials for obefazimod in ulcerative colitis treatment will be presented at the United European Gastroenterology Congress in Berlin on October 5.

The late-breaking abstract titled "Efficacy and Safety of Obefazimod in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Two, Phase 3, Randomised, Double-Blind, Placebo-Controlled, 8-Week Induction Trials" will showcase data from the company’s lead drug candidate.

A second presentation scheduled for October 6 will focus on obefazimod’s efficacy in patient subsets with and without prior inadequate response to advanced therapies.

"These findings are crucial steps towards potentially offering a novel, first-in-class oral treatment option for patients who urgently need new therapeutic approaches," said Fabio Cataldi, Chief Medical Officer of Abivax, in a press release statement.

The clinical-stage biotechnology company is developing obefazimod (ABX464) as a therapy that harnesses the body’s natural regulatory mechanisms to stabilize immune response in patients with chronic inflammatory diseases.

The presentations will take place at the UEG Congress running from October 4-7, 2025, where researchers will share data on the drug’s clinical activity and safety profile in treating moderately to severely active ulcerative colitis during the 8-week induction trials. InvestingPro subscribers can access 12 additional ProTips and detailed financial metrics to better understand the company’s investment potential.

In other recent news, Abivax has been the focus of several significant developments. The company is set to present data from its Phase 3 trials of obefazimod for ulcerative colitis at the United European Gastroenterology Congress in Berlin, with the presentation scheduled for October 6. This follows analyses from Piper Sandler, which raised Abivax’s stock price target to $112, citing promising Phase 3 data and increased revenue potential for early-line ulcerative colitis treatment. Similarly, JMP Securities has increased its price target for Abivax to $114, maintaining a Market Outperform rating, as they anticipate further analyses of obefazimod’s efficacy.

Meanwhile, Guggenheim has reiterated a Buy rating for Abivax, setting a price target of $101, buoyed by promising data in the inflammatory bowel disease space. The company’s drug, obefazimod, continues to draw attention as it competes with other treatments like Eli Lilly’s MORF-057. Additionally, JMP Securities has maintained its Market Outperform rating for Rapport Therapeutics, with a price target of $77, following strong clinical trial results. These developments underscore the ongoing interest and positive outlook from analysts regarding Abivax’s potential in the treatment of ulcerative colitis.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.